Literature-based immunization recommendations for XXXX requiring immunosuppressive medications for autoimmune bullous dermatoses.

@entity1 @entity66 @entity14086 @entity281 @entity7248
UNASSIGNED: Autoimmune bullous diseases, such as pemphigus, @entity7248 , and @entity14086 , are uniquely associated with vulnerability in the mucocutaneous barrier against @entity281 . The management of immunobullous diseases is complex and may at times require immunosuppressive medications. Iatrogenic immunosuppression may increase susceptibility to vaccine-preventable illnesses. Currently, there are no guidelines to assist the clinician treating @entity1 with @entity66 regarding the delivery of various vaccinations. The aim of this review is to provide recommendations for immunization in the unique setting of @entity66 . Recommendations are based on careful review of the literature in other conditions requiring iatrogenic immunosuppression, as well as the most recent Centers for Disease Control and Prevention guidelines. Immunization with nonlive vaccines appears to be a safe and effective strategy for preventing @entity281 in the particularly susceptible @entity1 with @entity66 . Opportunities for live vaccine administration may become available at lower levels of immune suppression or during clinical remission when immunosuppressive regimens can be reduced. Anticipatory vaccination before the initiation of iatrogenic immunosuppression is ideal. Although immunologic response to vaccination may be suboptimal during immunosuppression, nonlive vaccination is strongly recommended for this @entity1 population.
